Trelagliptin succinate is an oral antidiabetic drug used to treat type 2 diabetes mellitus. It works by inhibiting the DPP-4 (dipeptidyl peptidase-4) enzyme, thereby increasing insulin secretion and lowering blood glucose levels. A key feature is its once-weekly dosing, which may improve patient compliance compared to daily DPP-4 inhibitors. It is grouped under the following drug class(es): DPP-4 inhibitors. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include zafatek, (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2, 4-dioxo-3 and 4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile succinate. Its PubChem CID is 44183569.
Trelagliptin succinate
| CAS No | 1029877-94-8 |
|---|---|
| Molecular Formula | C22H26FN5O6 |
| Molecular Weight | 475.5 g/mol |
| Synonyms | 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile;butanedioic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Trelagliptin succinate is an oral antidiabetic drug used to treat type 2 diabetes mellitus. It works by inhibiting the DPP-4 (dipeptidyl peptidase-4) enzyme, thereby increasing insulin secretion and lowering blood glucose levels.
The listed CAS number is 1029877-94-8.
The listed molecular formula is C22H26FN5O6.
The listed molecular weight is 475.5 g/mol.
2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile;butanedioic acid.
The source lists zafatek, (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2, 4-dioxo-3 and 4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile succinate.